HALOZYME THERAPEUTICS INC

Halozyme Therapeutics tops Zacks PEG cluster, spotlighting its hyaluronidase drug‑delivery tech and $12B market cap as a high‑growth biotech.

Halozyme Therapeutics tops Q2 estimates, boosts 2026 revenue to $1.84‑$1.91B, and lifts stock to a new 52‑week high driven by 50% royalty surge.

Halozyme Therapeutics delivers a record‑breaking Q2 2026, with 48% revenue growth and raised full‑year targets, proving its enzyme platform and partnership model are scaling.

Halozyme’s hyaluronidase platform boosts subcutaneous delivery, sparking durable responses in advanced HNSCC and unlocking new oncology growth opportunities.

Halozyme Therapeutics: Explore how its hyaluronidase platform powers next‑gen oncology and drug‑delivery breakthroughs, and why the $8.1 B biotech stock could be poised for growth.

Halozyme Therapeutics’ latest earnings reveal robust growth prospects in diabetes, cancer and drug‑delivery research, while navigating regulatory risks.

Halozyme Therapeutics’ recent Form 144 filing reveals a controlled share sale by a former officer, spotlighting its biotech focus on hyaluronidase tech and stable insider activity.

Halozyme’s FDA approval of the DARZALEX FASPRO‑based regimen, a first for hyaluronidase‑containing products, boosts RRMM treatment and investor confidence.

Halozyme Therapeutics Q4 2025 earnings preview: analysts forecast $2.16 EPS, $435M revenue, driven by hyaluronidase drug‑delivery growth and licensing deals.

Halozyme raises 2025 revenue outlook, expands hyaluronidase platform with Surf Bio acquisition—boosting drug‑delivery prospects in diabetes, oncology, dermatology and more.